HHLR ADVISORS, LTD.
Institutional investor · Portfolio as of Q4 2018
Top Holdings32 positions
BEIGENE LTD | 4.4M | $622.5M | 25.8% | $140.26 | 0.00% | 1 qtr | First report 0 |
JD.com Inc | 15M | $314.8M | 13.1% | $19.70 | 0.00% | 1 qtr | First report 0 |
CHINA BIOLOGIC PRODS HLDGS I | 2.8M | $208.8M | 8.7% | — | — | 1 qtr | First report 0 |
TAL EDUCATION GROUP- ADR | 7.5M | $199.5M | 8.3% | $26.78 | 0.00% | 1 qtr | First report 0 |
Alibaba Group Holding Ltd | 1.4M | $193.5M | 8.0% | $128.99 | 0.00% | 1 qtr | First report 0 |
Mondelez International Inc | 3.5M | $141.3M | 5.9% | $33.70 | 0.00% | 1 qtr | First report 0 |
FibroGen Inc | 2M | $92.7M | 3.8% | $1,120.75 | 0.00% | 1 qtr | First report 0 |
58.COM INC-ADR | 1.5M | $80.5M | 3.3% | — | — | 1 qtr | First report 0 |
Blueprint Medicines Corp | 1.4M | $77.1M | 3.2% | — | — | 1 qtr | First report 0 |
iKang Healthcare Group, Inc. | 2.9M | $59.6M | 2.5% | $20.34 | — | 1 qtr | First report 0 |
MYOKARDIA INC | 858,340 | $41.9M | 1.7% | — | — | 1 qtr | First report 0 |
LINE CORP | 1.2M | $41.2M | 1.7% | — | — | 1 qtr | First report 0 |
Kiniksa Pharmaceuticals Ltd | 1.4M | $39M | 1.6% | $24.87 | 0.00% | 1 qtr | First report 0 |
Pinduoduo Inc | 1.7M | $38.8M | 1.6% | $22.44 | 0.00% | 1 qtr | First report 0 |
Snap Inc | 6.9M | $38.2M | 1.6% | $5.71 | 0.00% | 1 qtr | First report 0 |
BRIGHT SCHOLAR ED HLDGS LTD | 4M | $36.7M | 1.5% | $34.72 | 0.00% | 1 qtr | First report 0 |
Bilibili Inc | 2.2M | $31.8M | 1.3% | $14.37 | 0.00% | 1 qtr | First report 0 |
Apellis Pharmaceuticals Inc | 2.2M | $29.4M | 1.2% | $13.25 | 0.00% | 1 qtr | First report 0 |
Tencent Music Entertainment Gr | 1.5M | $19.4M | 0.8% | $13.11 | 0.00% | 1 qtr | First report 0 |
LOXO ONCOLOGY INC COM | 131,300 | $18.4M | 0.8% | — | — | 1 qtr | First report 0 |
HHLR ADVISORS, LTD. manages $2.4B across 32 positions as of Q4 2018. Top holdings: ONC (25.8%), JD (13.1%), CBPO (8.7%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.
First quarter we have for this fund: 32 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $2.4B across 32 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR